Myriad Genetics Inc. (MYGN) News Headlines

▮ More

Date

Headline

11/4/2019 5:05:44 PM Myriad Genetics Lowers FY20 Financial Outlook; Shares Plunge

11/4/2019 4:11:00 PM Myriad Genetics Q1 Loss/share $0.28 Vs. Loss $0.01 Year Ago

10/21/2019 7:08:16 AM Myriad Genetics Names Mark Pollack Chief Medical Officer Of Myriad Neuroscience, Effective Jan. 15

9/16/2019 7:26:58 AM Myriad Genetics Enters Research Collaboration With University Of Leeds

8/22/2019 7:14:53 AM Myriad Genetics Applauds USPSTF Recommendation On BRCA-Related Cancer Prevention

8/13/2019 4:09:30 PM Myriad Genetics Inc. Q4 adjusted earnings of $0.41 per share

8/13/2019 4:08:36 PM Myriad Genetics Q4 Loss/share $0.06 Vs. Profit 0.20 Year Ago

8/13/2019 3:00:09 PM Myriad Genetics Q4 19 Earnings Conference Call At 4:30 PM ET

8/7/2019 7:26:51 AM Myriad To Seek FDA Approval Of BRACAnalysis CDx As A Companion Diagnostic For Lynparza In Men With MCRPC

6/19/2019 7:13:35 AM Myriad Genetics Gets Second Insurance Reimbursement Decision For BRACAnalysis

5/7/2019 4:14:18 PM Myriad Genetics Q3 Adjusted EPS $0.46 Vs $0.34 Last Year

5/7/2019 3:03:46 PM Myriad Genetics Q3 19 Earnings Conference Call At 4:30 PM ET

4/9/2019 7:07:45 AM Myriad Genetics Submits First Module Of Premarket Approval Application To FDA For MyChoice HRD CDx Test

2/5/2019 4:17:58 PM Myriad Genetics Inc. Q2 adjusted earnings of $0.38 per share

2/5/2019 4:06:56 PM Myriad Genetics Q2 EPS $0.03 Vs. $0.43 Year Ago

12/31/2018 7:13:17 AM Former Myriad Genetics CEO Peter Durkee Meldrum Passes Away

12/31/2018 7:07:15 AM Myriad Genetics Says Former CEO Peter Durkee Meldrum, 71, Passed Away On December 20, 2018

12/26/2018 7:18:21 AM Myriad Genetics Publishes Vectra Study In Journal Rheumatology

12/26/2018 7:14:48 AM Myriad Publishes Vectra Study In Journal Rheumatology

12/19/2018 7:09:13 AM Myriad Genetics : EndoPredict Test Receives Positive NICE Recommendation For Patients With Early Breast Cancer